BridgeBio Pharma Inc
BBIO: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$46.80 | Tkzhq | Fjzhlzkbw |
BridgeBio: Key Pipeline Candidate Acoramidis Drives Valuation for Long-Term Investors
We have initiated coverage of BridgeBio Pharma, a biotechnology firm focused on discovering and delivering transformative medicine for genetic diseases. We assign the firm a no-moat rating due to the substantial risk of value destruction, as a significant portion of its valuation hinges on one pipeline candidate, acoramidis. The shares appear undervalued against our $36.70 fair value estimate.